Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nirsevimab real-world effectiveness for RSV prevention in infants in southern China
ChiCTR2600127159Phase 4Not yet recruiting
- Sponsor
- Guangzhou Women and Children's Medical Center
- Start
- Jun 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of nirsevimab in respiratory syncytial virus disease (RSV), acute bronchitis, bronchiolitis and 2 more (2 arms), sponsored by Guangzhou Women and Children's Medical Center. Primary endpoint: RSV-related respiratory infection hospitalization rate. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
nirsevimab
03
Conditions
respiratory syncytial virus disease (RSV)acute bronchitisbronchiolitispneumoniaAirways Infection
Beyond the preview
Go deeper on ChiCTR2600127159.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600127159.